For research use only. Not for therapeutic Use.
Capadenoson (Cat.No:I004000) is a potent and selective adenosine A1 receptor agonist with potential cardiovascular benefits. It activates A1 receptors in the heart and blood vessels, causing vasodilation and reducing heart rate without significantly lowering blood pressure. Capadenoson has shown promising results in preclinical and clinical studies as a treatment for heart failure with preserved ejection fraction, a common and currently untreatable condition. It is currently being developed by Corvidia Therapeutics.
| Catalog Number | I004000 |
| CAS Number | 544417-40-5 |
| Synonyms | 2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitril |
| Molecular Formula | C25H18ClN5O2S2 |
| Purity | ≥95% |
| Target | Adenosine Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile |
| InChI | InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31) |
| InChIKey | CITWCLNVRIKQAF-UHFFFAOYSA-N |
| SMILES | N#CC1=C(C2=CC=C(OCCO)C=C2)C(C#N)=C(SCC3=CSC(C4=CC=C(Cl)C=C4)=N3)N=C1N |
| Reference | </br>1:Capadenoson, a clinically trialed partial adenosine A<sub>1</sub> receptor agonist, can stimulate adenosine A<sub>2B</sub> receptor biased agonism. Baltos JA, Vecchio EA, Harris MA, Qin CX, Ritchie RH, Christopoulos A, White PJ, May LT.Biochem Pharmacol. 2017 Mar 23. pii: S0006-2952(17)30160-0. doi: 10.1016/j.bcp.2017.03.014. [Epub ahead of print] PMID: 28344125 </br>2:Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists. Louvel J, Guo D, Soethoudt M, Mocking TA, Lenselink EB, Mulder-Krieger T, Heitman LH, IJzerman AP.Eur J Med Chem. 2015 Aug 28;101:681-91. doi: 10.1016/j.ejmech.2015.07.023. Epub 2015 Jul 15. PMID: 26210506 </br>3:The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Tendera M, Gaszewska-Żurek E, Parma Z, Ponikowski P, Jankowska E, Kawecka-Jaszcz K, Czarnecka D, Krzemińska-Pakuła M, Bednarkiewicz Z, Sosnowski M, Ochan Kilama M, Agrawal R.Clin Res Cardiol. 2012 Jul;101(7):585-91. doi: 10.1007/s00392-012-0430-8. Epub 2012 Feb 28. PMID: 22370739 |
